CoChat
Sign Up
Cited by 199Cytokine Signaling Pathways and InteractionsPsoriasis: Treatment and PathogenesisNF-κB Signaling Pathways

Contribution of STAT3 to inflammatory and fibrotic diseases and prospects for its targeting for treatment

Open access
Kasembeli, Moses M., Bharadwaj, Uddalak, Robinson, Prema, Tweardy, David J.·2018·International Journal of Molecular Sciences
DOI 10.3390/ijms19082299PMC PMC6121470
Open this paper in CoChat — free accountOpen PDF

Abstract

Signal transducer and activator of transcription (STAT) 3 plays a central role in the host response to injury. It is activated rapidly within cells by many cytokines, most notably those in the IL-6 family, leading to pro-proliferative and pro-survival programs that assist the host in regaining homeostasis. With persistent activation, however, chronic inflammation and fibrosis ensue, leading to a number of debilitating diseases. This review summarizes advances in our understanding of the role of STAT3 and its targeting in diseases marked by chronic inflammation and/or fibrosis with a focus on those with the largest unmet medical need.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms19082299

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 178

  1. [2]Greenhill C.J. Rose-John S. Lissilaa R. Ferlin W. Ernst M. Hertzog P.J. Mansell A. Jenkins B.J. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3 J. Immunol. 2011 186 1199 1208 10.4049/jimmunol.1002971 21148800 · DOI · Paper page
  2. [3]Caiello I. Minnone G. Holzinger D. Vogl T. Prencipe G. Manzo A. De Benedetti F. Strippoli R. IL-6 amplifies TLR mediated cytokine and chemokine production: Implications for the pathogenesis of rheumatic inflammatory diseases PLoS ONE 2014 9 e107886 10.1371/journal.pone.0107886 25271853 PMC4182736 · DOI
  3. [4]Moran A. Akcan Arikan A. Mastrangelo M.-A.A. Wu Y. Yu B. Poli V. Tweardy D.J. Prevention of trauma and hemorrhagic shock-mediated liver apoptosis by activation of stat3α Int. J. Clin. Exp. Med. 2008 1 213 247 18997875 PMC2581418
  4. [5]Moran A. Tsimelzon A.I. Mastrangelo M.-A.A. Wu Y. Yu B. Hilsenbeck S.G. Poli V. Tweardy D.J. Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3 Clin. Transl. Sci. 2009 2 41 49 10.1111/j.1752-8062.2008.00076.x 20443866 PMC5350783 · DOI · Paper page
  5. [6]Thacker S.A. Robinson P. Abel A. Tweardy D.J. Modulation of the unfolded protein response during hepatocyte and cardiomyocyte apoptosis in trauma/hemorrhagic shock Sci. Rep. 2013 3 1187 10.1038/srep01187 23378918 PMC3561621 · DOI · Paper page
  6. [7]Akinbami L.J. Moorman J.E. Bailey C. Zahran H.S. King M. Johnson C.A. Liu X. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010 NCHS Data Brief 2012 94 1 8 22617340
  7. [8]Fahy J.V. Eosinophilic and neutrophilic inflammation in asthma: Insights from clinical studies Proc. Am. Thorac. Soc. 2009 6 256 259 10.1513/pats.200808-087RM 19387026 · DOI
  8. [9]Wenzel S.E. Asthma: Defining of the persistent adult phenotypes Lancet 2006 368 804 813 10.1016/S0140-6736(06)69290-8 16935691 · DOI
  9. [10]Lin T.-Y. Poon A.H. Hamid Q. Asthma phenotypes and endotypes Curr. Opin. Pulm. Med. 2013 19 18 23 10.1097/MCP.0b013e32835b10ec 23114560 · DOI
  10. [11]American Thoracic Society Proceedings of the ATS workshop on refractory asthma: Current understanding, recommendations, and unanswered questions Am. J. Respir. Crit. Care Med. 2000 162 2341 2351 10.1164/ajrccm.162.6.ats9-00 11112161 · DOI
  11. [12]Al-Ramli W. Prefontaine D. Chouiali F. Martin J.G. Olivenstein R. Lemiere C. Hamid Q. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma J. Allergy Clin. Immunol. 2009 123 1185 1187 10.1016/j.jaci.2009.02.024 19361847 · DOI
  12. [13]McKinley L. Alcorn J.F. Peterson A. Dupont R.B. Kapadia S. Logar A. Henry A. Irvin C.G. Piganelli J.D. Ray A. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice J. Immunol. 2008 181 4089 4097 10.4049/jimmunol.181.6.4089 18768865 PMC3638757 · DOI
  13. [14]Simeone-Penney M.C. Severgnini M. Tu P. Homer R.J. Mariani T.J. Cohn L. Simon A.R. Airway epithelial STAT3 is required for allergic inflammation in a murine model of asthma J. Immunol. 2007 178 6191 6199 10.4049/jimmunol.178.10.6191 17475846 · DOI
  14. [15]Stritesky G.L. Muthukrishnan R. Sehra S. Goswami R. Pham D. Travers J. Nguyen E.T. Levy D.E. Kaplan M.H. The transcription factor STAT3 is required for T helper 2 cell development Immunity 2011 34 39 49 10.1016/j.immuni.2010.12.013 21215659 PMC3040244 · DOI
  15. [16]Lim H. Cho M. Choi G. Na H. Chung Y. Dynamic control of Th2 cell responses by STAT3 during allergic lung inflammation in mice Int. Immunopharmacol. 2015 28 846 853 10.1016/j.intimp.2015.03.051 25871878 · DOI
  16. [17]Ma C.S. Chew G.Y.J. Simpson N. Priyadarshi A. Wong M. Grimbacher B. Fulcher D.A. Tangye S.G. Cook M.C. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3 J. Exp. Med. 2008 205 1551 1557 10.1084/jem.20080218 18591410 PMC2442632 · DOI · Paper page
  17. [18]Milner J.D. Brenchley J.M. Laurence A. Freeman A.F. Hill B.J. Elias K.M. Kanno Y. Spalding C. Elloumi H.Z. Paulson M.L. Impaired th17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome Nature 2008 452 773 776 10.1038/nature06764 18337720 PMC2864108 · DOI · Paper page
  18. [19]Chen Z. Laurence A. O’Shea J.J. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation Semin. Immunol. 2007 19 400 408 10.1016/j.smim.2007.10.015 18166487 PMC2323678 · DOI · Paper page
  19. [20]Jin W. Dong C. IL-17 cytokines in immunity and inflammation Emerg. Microbes Infect. 2013 2 e60 10.1038/emi.2013.58 26038490 PMC3820987 · DOI
  20. [21]Wang Q. Li H. Yao Y. Xia D. Zhou J. The overexpression of heparin-binding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model J. Immunol. 2010 185 834 841 10.4049/jimmunol.0901490 20530256 · DOI
  21. [22]Gavino A.C. Nahmod K. Bharadwaj U. Makedonas G. Tweardy D.J. STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model Allergy 2016 71 1684 1692 10.1111/all.12937 27225906 · DOI · Paper page
  22. [23]Howell M.D. Fitzsimons C. Smith P.A. JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease Ann. Allergy Asthma Immunol. 2018 120 367 375 10.1016/j.anai.2018.02.012 29454096 · DOI
  23. [24]Bel E.H. Ortega H.G. Pavord I.D. Glucocorticoids and mepolizumab in eosinophilic asthma N. Engl. J. Med. 2014 371 2433 2434 10.1056/NEJMoa1403291 25517711 · DOI
  24. [25]Bel E.H. Wenzel S.E. Thompson P.J. Prazma C.M. Keene O.N. Yancey S.W. Ortega H.G. Pavord I.D. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N. Engl. J. Med. 2014 371 1189 1197 10.1056/NEJMoa1403291 25199060 · DOI
  25. [26]Ortega H.G. Liu M.C. Pavord I.D. Brusselle G.G. FitzGerald J.M. Chetta A. Humbert M. Katz L.E. Keene O.N. Yancey S.W. Mepolizumab treatment in patients with severe eosinophilic asthma N. Engl. J. Med. 2014 371 1198 1207 10.1056/NEJMoa1403290 25199059 · DOI
  26. [27]Pavord I.D. Korn S. Howarth P. Bleecker E.R. Buhl R. Keene O.N. Ortega H. Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial Lancet 2012 380 651 659 10.1016/S0140-6736(12)60988-X 22901886 · DOI
  27. [28]Wiegman C.H. Russell K.E. Seiffert J. Rossios C. Adcock I.M. Rothaul A. Main M. Morgan F. The Selective pan-Janus Kinase (JAK) Inhibitor VR588 Demonstrates Potent Anti-Inflammatory Activity in a Murine Chronic House Dust Mite (HDM) Model of Asthma Proceedings of the American Thoracic Society International Conference Abstracts Denver, CO, USA 15–20 May 2015 American Thoracic Society New York, NY, USA 2015 A6435
  28. [29]Oskeritzian C.A. Hait N.C. Wedman P. Chumanevich A. Kolawole E.M. Price M.M. Falanga Y.T. Harikumar K.B. Ryan J.J. Milstien S. The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses J. Allergy Clin. Immunol. 2015 135 1008 1018.e1 10.1016/j.jaci.2014.10.044 25512083 PMC4388821 · DOI
  29. [31]Ito H. Takazoe M. Fukuda Y. Hibi T. Kusugami K. Andoh A. Matsumoto T. Yamamura T. Azuma J. Nishimoto N. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease Gastroenterology 2004 126 989 996 discussion 947 10.1053/j.gastro.2004.01.012 15057738 · DOI · Paper page
  30. [34]Herrlinger K.R. Diculescu M. Fellermann K. Hartmann H. Howaldt S. Nikolov R. Petrov A. Reindl W. Otte J.M. Stoynov S. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study J. Crohn’s Colitis 2013 7 636 643 10.1016/j.crohns.2012.09.016 23078909 · DOI
  31. [35]McGeachy M.J. Chen Y. Tato C.M. Laurence A. Joyce-Shaikh B. Blumenschein W.M. McClanahan T.K. O’Shea J.J. Cua D.J. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo Nat. Immunol. 2009 10 314 324 10.1038/ni.1698 19182808 PMC2945605 · DOI · Paper page
  32. [36]Sandborn W.J. Feagan B.G. Fedorak R.N. Scherl E. Fleisher M.R. Katz S. Johanns J. Blank M. Rutgeerts P. Ustekinumab Crohn’s Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease Gastroenterology 2008 135 1130 1141 10.1053/j.gastro.2008.07.014 18706417 · DOI
  33. [37]Anderson C.A. Boucher G. Lees C.W. Franke A. D’Amato M. Taylor K.D. Lee J.C. Goyette P. Imielinski M. Latiano A. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 Nat. Genet. 2011 43 246 252 10.1038/ng.764 21297633 PMC3084597 · DOI
  34. [38]Durant L. Watford W.T. Ramos H.L. Laurence A. Vahedi G. Wei L. Takahashi H. Sun H.W. Kanno Y. Powrie F. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis Immunity 2010 32 605 615 10.1016/j.immuni.2010.05.003 20493732 PMC3148263 · DOI
  35. [39]Uckun F.M. Tibbles H. Ozer Z. Qazi S. Vassilev A. Anti-inflammatory activity profile of JANEX-1 in preclinical animal models Bioorg. Med. Chem. 2008 16 1287 1298 10.1016/j.bmc.2007.10.066 18024136 · DOI
  36. [40]Sandborn W.J. Ghosh S. Panes J. Vranic I. Su C. Rousell S. Niezychowski W. Study A.I. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N. Engl. J. Med. 2012 367 616 624 10.1056/NEJMoa1112168 22894574 · DOI
  37. [41]Cottone M. Orlando A. Papi C. Tofacitinib in active ulcerative colitis N. Engl. J. Med. 2012 367 1959 1961 23150971
  38. [42]De Vries L.C.S. Wildenberg M.E. De Jonge W.J. D’Haens G.R. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease J Crohn’s Colitis 2017 11 885 893 10.1093/ecco-jcc/jjx003 28158411 PMC5881740 · DOI
  39. [43]Ananthakrishnan A.N. Filgotinib for Crohn’s disease-expanding treatment options Lancet 2017 389 228 229 10.1016/S0140-6736(16)32538-7 27988141 · DOI
  40. [44]Sandborn W.J. Feagan B.G. Panes J. D’Haens G.R. Colombel J.F. Zhou Q. Huang B. Enejosa J.V. Pangan A.L. Lacerda A.P. Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn’s Disease: Results from Celest Gastroenterology 2017 152 S1308 S1309 10.1016/S0016-5085(17)34357-3 · DOI
  41. [47]Bonetto A. Aydogdu T. Jin X. Zhang Z. Zhan R. Puzis L. Koniaris L.G. Zimmers T.A. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia Am. J. Physiol. Endocrinol. Metab. 2012 303 E410 E421 10.1152/ajpendo.00039.2012 22669242 PMC3423125 · DOI · Paper page
  42. [48]Zhang L. Pan J. Dong Y. Tweardy D.J. Dong Y. Garibotto G. Mitch W.E. Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass Cell Metab. 2013 18 368 379 10.1016/j.cmet.2013.07.012 24011072 PMC3794464 · DOI
  43. [49]Zhang S. Suvannasankha A. Crean C.D. White V.L. Chen C.-S. Farag S.S. The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells Int. J. Cancer 2011 129 204 213 10.1002/ijc.25660 20824695 PMC4201584 · DOI
  44. [50]Cerchione C. Peluso I. Nappi D. Pareto A.E. Picardi M. Martinelli V. Pane F. Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis Ann. Hematol. 2017 96 697 699 10.1007/s00277-017-2938-5 28197723 PMC5334413 · DOI · Paper page
  45. [51]Jatoi A. Anti-inflammatory therapy: Exploring exercise, serum-derived bovine immunoglobulin/protein isolates, and ruxolitinib for the cancer-associated weight loss syndrome Curr. Opin. Support. Palliat. Care 2013 7 339 341 10.1097/SPC.0000000000000014 24189891 · DOI
  46. [52]Milara J. Hernandez G. Ballester B. Morell A. Roger I. Montero P. Escriva J. Lloris J.M. Molina-Molina M. Morcillo E. The JAK2 pathway is activated in idiopathic pulmonary fibrosis Respir. Res. 2018 19 24 10.1186/s12931-018-0728-9 29409529 PMC5801676 · DOI · Paper page
  47. [53]Milara J. Ballester B. Morell A. Ortiz J.L. Escriva J. Fernandez E. Perez-Vizcaino F. Cogolludo A. Pastor E. Artigues E. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: An experimental study Thorax 2018 73 519 529 10.1136/thoraxjnl-2017-210728 29440315 · DOI
  48. [54]Sallam A.M. Esmat A. Abdel-Naim A.B. Cucurbitacin-B attenuates CCl4-induced hepatic fibrosis in mice through inhibition of STAT-3 Chem. Biol. Drug Des. 2018 91 933 941 10.1111/cbdd.13160 29250925 · DOI
  49. [55]Derenzini E. Younes A. Targeting the JAK-STAT pathway in lymphoma: A focus on pacritinib Expert Opin. Investig. Drugs 2013 22 775 785 10.1517/13543784.2013.775244 23442043 · DOI
  50. [56]Komrokji R.S. Seymour J.F. Roberts A.W. Wadleigh M. To L.B. Scherber R. Turba E. Dorr A. Zhu J. Wang L. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis Blood 2015 125 2649 2655 10.1182/blood-2013-02-484832 25762180 PMC4490373 · DOI
  51. [57]Mughal T.I. Vaddi K. Sarlis N.J. Verstovsek S. Myelofibrosis-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes Int. J. Gen. Med. 2014 7 89 101 24501543 PMC3912063
  52. [58]Vannucchi A.M. Kantarjian H.M. Kiladjian J.-J. Gotlib J. Cervantes F. Mesa R.A. Sarlis N.J. Peng W. Sandor V. Gopalakrishna P. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis Haematologica 2015 100 1139 1145 10.3324/haematol.2014.119545 26069290 PMC4800694 · DOI · Paper page
  53. [59]Verstovsek S. Mesa R.A. Gotlib J. Levy R.S. Gupta V. DiPersio J.F. Catalano J.V. Deininger M.W.N. Miller C.B. Silver R.T. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 3-year follow-up of COMFORT-I Haematologica 2015 100 479 488 10.3324/haematol.2014.115840 25616577 PMC4380721 · DOI
  54. [60]Pang M. Ma L. Gong R. Tolbert E. Mao H. Ponnusamy M. Chin Y.E. Yan H. Dworkin L.D. Zhuang S. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy Kidney Int. 2010 78 257 268 10.1038/ki.2010.154 20520592 · DOI · Paper page
  55. [61]Dong Y. Lu B. Zhang X. Zhang J. Lai L. Li D. Wu Y. Song Y. Luo J. Pang X. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway Carcinogenesis 2010 31 2097 2104 10.1093/carcin/bgq167 20732905 · DOI
  56. [62]Bharadwaj U. Eckols T.K. Xu X. Kasembeli M.M. Chen Y. Adachi M. Song Y. Mo Q. Lai S.Y. Tweardy D.J. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma Oncotarget 2016 7 26307 26330 10.18632/oncotarget.8368 27027445 PMC5041982 · DOI
  57. [64]Pedroza M. To S. Assassi S. Wu M. Tweardy D. Agarwal S.K. Role of STAT3 in skin fibrosis and transforming growth factor beta signalling Rheumatology 2017 10.1093/rheumatology/kex347 29029263 PMC6152423 · DOI
  58. [65]Jung K.H. Yoo W. Stevenson H.L. Deshpande D. Shen H. Gagea M. Yoo S.-Y. Wang J. Eckols T.K. Bharadwaj U. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice Clin. Cancer Res. 2017 23 5537 5546 10.1158/1078-0432.CCR-16-2253 28533225 PMC5873583 · DOI · Paper page
  59. [66]Mohammed S. Harikumar K.B. Sphingosine 1-Phosphate: A Novel Target for Lung Disorders Front. Immunol. 2017 8 296 10.3389/fimmu.2017.00296 28352271 PMC5348531 · DOI
  60. [68]Bharadwaj U. Kasembeli M.M. Tweardy D.J. STAT3 Inhibitors in Cancer: A Comprehensive Update STAT Inhibitors in Cancer Ward A.C. STAT Inhibitors in Cancer Springer International Publishing Cham, Switzerland 2016 95 161
  61. [69]Choy D.F. Hart K.M. Borthwick L.A. Shikotra A. Nagarkar D.R. Siddiqui S. Jia G. Ohri C.M. Doran E. Vannella K.M. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma Sci. Transl. Med. 2015 7 301ra129 10.1126/scitranslmed.aab3142 26290411 · DOI · Paper page
  62. [70]Dahlhamer J.M. Zammitti E.P. Ward B.W. Wheaton A.G. Croft J.B. Prevalence of Inflammatory Bowel Disease among Adults Aged >/=18 Years—United States, 2015 MMWR Morb. Mortal. Wkly. Rep. 2016 65 1166 1169 10.15585/mmwr.mm6542a3 27787492 · DOI
  63. [71]Baumgart D.C. Carding S.R. Inflammatory bowel disease: Cause and immunobiology Lancet 2007 369 1627 1640 10.1016/S0140-6736(07)60750-8 17499605 · DOI · Paper page
  64. [72]Baumgart D.C. Sandborn W.J. Inflammatory bowel disease: Clinical aspects and established and evolving therapies Lancet 2007 369 1641 1657 10.1016/S0140-6736(07)60751-X 17499606 · DOI
  65. [74]Neurath M.F. Cytokines in inflammatory bowel disease Nat. Rev. Immunol. 2014 14 329 342 10.1038/nri3661 24751956 · DOI · Paper page
  66. [75]Ha F. Khalil H. Crohn’s disease: A clinical update Therap. Adv. Gastroenterol. 2015 8 352 359 10.1177/1756283X15592585 26557891 PMC4622286 · DOI
  67. [76]Kalla R. Ventham N.T. Satsangi J. Arnott I.D. Crohn’s disease BMJ 2014 349 g6670 10.1136/bmj.g6670 25409896 · DOI
  68. [77]Baumgart D.C. Sandborn W.J. Crohn’s disease Lancet 2012 380 1590 1605 10.1016/S0140-6736(12)60026-9 22914295 · DOI
  69. [78]Juckett G. Trivedi R. Evaluation of chronic diarrhea Am. Fam. Phys. 2011 84 1119 1126 22085666
  70. [79]Sands B.E. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation Gastroenterology 2004 126 1518 1532 10.1053/j.gastro.2004.02.072 15168364 · DOI
  71. [80]Castano-Milla C. Chaparro M. Gisbert J.P. Systematic review with meta-analysis: The declining risk of colorectal cancer in ulcerative colitis Aliment. Pharmacol. Ther. 2014 39 645 659 10.1111/apt.12651 24612141 · DOI
  72. [81]Freeman H.J. Colorectal cancer risk in Crohn’s disease World J. Gastroenterol. 2008 14 1810 1811 10.3748/wjg.14.1810 18350616 PMC2700422 · DOI
  73. [82]Harpaz N. Ward S.C. Mescoli C. Itzkowitz S.H. Polydorides A.D. Precancerous lesions in inflammatory bowel disease Best Pract. Res. Clin. Gastroenterol. 2013 27 257 267 10.1016/j.bpg.2013.03.014 23809244 · DOI
  74. [84]Jostins L. Ripke S. Weersma R.K. Duerr R.H. McGovern D.P. Hui K.Y. Lee J.C. Schumm L.P. Sharma Y. Anderson C.A. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease Nature 2012 491 119 124 10.1038/nature11582 23128233 PMC3491803 · DOI · Paper page
  75. [85]Lees C.W. Barrett J.C. Parkes M. Satsangi J. New IBD genetics: Common pathways with other diseases Gut 2011 60 1739 1753 10.1136/gut.2009.199679 21300624 · DOI · Paper page
  76. [86]Mudter J. Neurath M.F. Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance Inflamm. Bowel Dis. 2007 13 1016 1023 10.1002/ibd.20148 17476678 · DOI
  77. [87]Strober W. Fuss I.J. Blumberg R.S. The immunology of mucosal models of inflammation Annu. Rev. Immunol. 2002 20 495 549 10.1146/annurev.immunol.20.100301.064816 11861611 · DOI
  78. [88]Levy D.E. Darnell J.E.J. Stats: Transcriptional control and biological impact Nat. Rev. Mol. Cell Biol. 2002 3 651 662 10.1038/nrm909 12209125 · DOI · Paper page
  79. [89]Rawlings J.S. Rosler K.M. Harrison D.A. The JAK/STAT signaling pathway J. Cell Sci. 2004 117 1281 1283 10.1242/jcs.00963 15020666 · DOI · Paper page
  80. [90]Lovato P. Brender C. Agnholt J. Kelsen J. Kaltoft K. Svejgaard A. Eriksen K.W. Woetmann A. Odum N. Constitutive STAT3 activation in intestinal T cells from patients with Crohn’s disease J. Biol. Chem. 2003 278 16777 16781 10.1074/jbc.M207999200 12615922 · DOI
  81. [91]Mudter J. Weigmann B. Bartsch B. Kiesslich R. Strand D. Galle P.R. Lehr H.A. Schmidt J. Neurath M.F. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases Am. J. Gastroenterol. 2005 100 64 72 10.1111/j.1572-0241.2005.40615.x 15654782 · DOI
  82. [92]Musso A. Dentelli P. Carlino A. Chiusa L. Repici A. Sturm A. Fiocchi C. Rizzetto M. Pegoraro L. Sategna-Guidetti C. Signal transducers and activators of transcription 3 signaling pathway: An essential mediator of inflammatory bowel disease and other forms of intestinal inflammation Inflamm. Bowel Dis. 2005 11 91 98 10.1097/00054725-200502000-00001 15677901 · DOI
  83. [93]Atreya R. Mudter J. Finotto S. Mullberg J. Jostock T. Wirtz S. Schutz M. Bartsch B. Holtmann M. Becker C. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in crohn disease and experimental colitis in vivo Nat. Med. 2000 6 583 588 10.1038/75068 10802717 · DOI · Paper page
  84. [94]Pickert G. Neufert C. Leppkes M. Zheng Y. Wittkopf N. Warntjen M. Lehr H.A. Hirth S. Weigmann B. Wirtz S. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing J. Exp. Med. 2009 206 1465 1472 10.1084/jem.20082683 19564350 PMC2715097 · DOI · Paper page
  85. [95]Suzuki A. Hanada T. Mitsuyama K. Yoshida T. Kamizono S. Hoshino T. Kubo M. Yamashita A. Okabe M. Takeda K. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation J. Exp. Med. 2001 193 471 481 10.1084/jem.193.4.471 11181699 PMC2195913 · DOI
  86. [96]Takeda K. Clausen B.E. Kaisho T. Tsujimura T. Terada N. Forster I. Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils Immunity 1999 10 39 49 10.1016/S1074-7613(00)80005-9 10023769 · DOI · Paper page
  87. [97]Yamamoto M. Yoshizaki K. Kishimoto T. Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis J. Immunol. 2000 164 4878 4882 10.4049/jimmunol.164.9.4878 10779797 · DOI · Paper page
  88. [98]Atreya R. Neurath M.F. Signaling molecules: The pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer Curr. Drug Targets 2008 9 369 374 10.2174/138945008784221116 18473764 · DOI
  89. [100]Maritano D. Sugrue M.L. Tininini S. Dewilde S. Strobl B. Fu X. Murray-Tait V. Chiarle R. Poli V. The STAT3 isoforms alpha and beta have unique and specific functions Nat. Immunol. 2004 5 401 409 10.1038/ni1052 15021879 · DOI · Paper page
  90. [101]Bilsborough J. Viney J.L. From model to mechanism: Lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease Expert Opin. Drug Discov. 2006 1 69 83 10.1517/17460441.1.1.69 23506033 · DOI
  91. [102]Liu Z. Geboes K. Colpaert S. D’Haens G.R. Rutgeerts P. Ceuppens J.L. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production J. Immunol. 2000 164 3608 3615 10.4049/jimmunol.164.7.3608 10725717 · DOI
  92. [103]Nguyen P.M. Putoczki T.L. Ernst M. STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease? J. Interferon Cytokine Res. 2015 35 340 350 10.1089/jir.2014.0225 25760898 PMC4426323 · DOI
  93. [104]Pallone F. Fina D. Caruso R. Monteleone G. Role of IL-21 in inflammatory bowel disease Expert Rev. Clin. Immunol. 2010 6 537 541 10.1586/eci.10.44 20594126 · DOI
  94. [105]Sanchez-Munoz F. Dominguez-Lopez A. Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease World J. Gastroenterol. 2008 14 4280 4288 10.3748/wjg.14.4280 18666314 PMC2731177 · DOI · Paper page
  95. [106]Rebe C. Vegran F. Berger H. Ghiringhelli F. STAT3 activation: A key factor in tumor immunoescape JAK-STAT 2013 2 e23010 10.4161/jkst.23010 24058791 PMC3670267 · DOI
  96. [107]Ito R. Shin-Ya M. Kishida T. Urano A. Takada R. Sakagami J. Imanishi J. Kita M. Ueda Y. Iwakura Y. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice Clin. Exp. Immunol. 2006 146 330 338 10.1111/j.1365-2249.2006.03214.x 17034586 PMC1942055 · DOI
  97. [108]Carpenter R.L. Lo H.-W. STAT3 Target Genes Relevant to Human Cancers Cancers 2014 6 897 925 10.3390/cancers6020897 24743777 PMC4074809 · DOI · Paper page
  98. [109]Piekkala M. Hagstrom J. Tanskanen M. Rintala R. Haglund C. Kolho K.-L. Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery World J. Gastroenterol. 2013 19 3272 3280 10.3748/wjg.v19.i21.3272 23745029 PMC3671079 · DOI
  99. [110]Ito R. Kita M. Shin-Ya M. Kishida T. Urano A. Takada R. Sakagami J. Imanishi J. Iwakura Y. Okanoue T. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice Biochem. Biophys. Res. Commun. 2008 377 12 16 10.1016/j.bbrc.2008.09.019 18796297 · DOI
  100. [111]Kanai T. Watanabe M. Okazawa A. Sato T. Yamazaki M. Okamoto S. Ishii H. Totsuka T. Iiyama R. Okamoto R. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn’s disease Gastroenterology 2001 121 875 888 10.1053/gast.2001.28021 11606501 · DOI
  101. [112]Nishiwaki T. Ina K. Goto H. Watanabe O. Tsuzuki T. Furuta R. Ando T. Hibi K. Kusugami K. Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease J. Gastroenterol. 2005 40 128 136 10.1007/s00535-004-1510-y 15770395 · DOI
  102. [113]Ohta N. Hiroi T. Kweon M.N. Kinoshita N. Jang M.H. Mashimo T. Miyazaki J. Kiyono H. IL-15-dependent activation-induced cell death-resistant Th1 type CD8 alpha beta+NK1.1+ T cells for the development of small intestinal inflammation J. Immunol. 2002 169 460 468 10.4049/jimmunol.169.1.460 12077277 · DOI
  103. [114]Pizarro T.T. Michie M.H. Bentz M. Woraratanadharm J. Smith M.F.J. Foley E. Moskaluk C.A. Bickston S.J. Cominelli F. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: Expression and localization in intestinal mucosal cells J. Immunol. 1999 162 6829 6835 10352304
  104. [115]Sengupta N. MacDonald T.T. The role of matrix metalloproteinases in stromal/epithelial interactions in the gut Physiology 2007 22 401 409 10.1152/physiol.00027.2007 18073413 · DOI
  105. [116]Uhlig H.H. McKenzie B.S. Hue S. Thompson C. Joyce-Shaikh B. Stepankova R. Robinson N. Buonocore S. Tlaskalova-Hogenova H. Cua D.J. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology Immunity 2006 25 309 318 10.1016/j.immuni.2006.05.017 16919486 · DOI
  106. [117]Yen D. Cheung J. Scheerens H. Poulet F. McClanahan T. McKenzie B. Kleinschek M.A. Owyang A. Mattson J. Blumenschein W. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6 J. Clin. Investig. 2006 116 1310 1316 10.1172/JCI21404 16670770 PMC1451201 · DOI
  107. [118]Zhang Z. Zheng M. Bindas J. Schwarzenberger P. Kolls J.K. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis Inflamm. Bowel Dis. 2006 12 382 388 10.1097/01.MIB.0000218764.06959.91 16670527 · DOI
  108. [119]Herrlinger K.R. Witthoeft T. Raedler A. Bokemeyer B. Krummenerl T. Schulzke J.D. Boerner N. Kueppers B. Emmrich J. Mescheder A. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn’s disease Am. J. Gastroenterol. 2006 101 793 797 10.1111/j.1572-0241.2005.00356.x 16635225 · DOI
  109. [120]Katakura K. Lee J. Rachmilewitz D. Li G. Eckmann L. Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis J. Clin. Investig. 2005 115 695 702 10.1172/JCI22996 15765149 PMC1051992 · DOI
  110. [121]Li B. Alli R. Vogel P. Geiger T.L. IL-10 modulates DSS-induced colitis through a macrophage-ROS-NO axis Mucosal Immunol. 2014 7 869 878 10.1038/mi.2013.103 24301657 PMC4045662 · DOI
  111. [122]Musch E. Andus T. Kruis W. Raedler A. Spehlmann M. Schreiber S. Krakamp B. Malek M. Malchow H. Zavada F. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: A randomized, double-blind, placebo-controlled trial Clin. Gastroenterol. Hepatol. 2005 3 581 586 10.1016/S1542-3565(05)00208-9 15952100 · DOI
  112. [123]Qiu B.S. Pfeiffer C.J. Keith J.C.J. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats Dig. Dis. Sci. 1996 41 1625 1630 10.1007/BF02087911 8769290 · DOI
  113. [124]Sugimoto K. Ogawa A. Mizoguchi E. Shimomura Y. Andoh A. Bhan A.K. Blumberg R.S. Xavier R.J. Mizoguchi A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis J. Clin. Investig. 2008 118 534 544 10.1172/JCI33194 18172556 PMC2157567 · DOI
  114. [126]Zindl C.L. Lai J.F. Lee Y.K. Maynard C.L. Harbour S.N. Ouyang W. Chaplin D.D. Weaver C.T. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis Proc. Natl. Acad. Sci. USA 2013 110 12768 12773 10.1073/pnas.1300318110 23781104 PMC3732935 · DOI
  115. [127]Coskun M. Salem M. Pedersen J. Nielsen O.H. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease Pharmacol. Res. 2013 76 1 8 10.1016/j.phrs.2013.06.007 23827161 · DOI
  116. [128]Von Haehling S. Anker S.D. Prevalence, incidence and clinical impact of cachexia: Facts and numbers-update 2014 J. Cachexia Sarcopenia Muscle 2014 5 261 263 10.1007/s13539-014-0164-8 25384990 PMC4248411 · DOI
  117. [129]Fearon K. Strasser F. Anker S.D. Bosaeus I. Bruera E. Fainsinger R.L. Jatoi A. Loprinzi C. MacDonald N. Mantovani G. Definition and classification of cancer cachexia: An international consensus Lancet Oncol. 2011 12 489 495 10.1016/S1470-2045(10)70218-7 21296615 · DOI
  118. [131]Latres E. Amini A.R. Amini A.A. Griffiths J. Martin F.J. Wei Y. Lin H.C. Yancopoulos G.D. Glass D.J. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway J. Biol. Chem. 2005 280 2737 2744 10.1074/jbc.M407517200 15550386 · DOI
  119. [132]Glass D.J. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy Curr. Top. Microbiol. Immunol. 2010 346 267 278 20593312
  120. [133]Kotas M.E. Medzhitov R. Homeostasis, inflammation, and disease susceptibility Cell 2015 160 816 827 10.1016/j.cell.2015.02.010 25723161 PMC4369762 · DOI · Paper page
  121. [135]Argiles J.M. Lopez-Soriano F.J. Busquets S. Counteracting inflammation: A promising therapy in cachexia Crit. Rev. Oncog. 2012 17 253 262 10.1615/CritRevOncog.v17.i3.30 22831156 · DOI
  122. [137]Miyamoto Y. Hanna D.L. Zhang W. Baba H. Lenz H.-J. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment Clin. Cancer Res. 2016 22 3999 4004 10.1158/1078-0432.CCR-16-0495 27340276 PMC4987228 · DOI · Paper page
  123. [138]Zhao J. Brault J.J. Schild A. Cao P. Sandri M. Schiaffino S. Lecker S.H. Goldberg A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells Cell Metab. 2007 6 472 483 10.1016/j.cmet.2007.11.004 18054316 · DOI · Paper page
  124. [140]Johnston A.J. Murphy K.T. Jenkinson L. Laine D. Emmrich K. Faou P. Weston R. Jayatilleke K.M. Schloegel J. Talbo G. Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival Cell 2015 162 1365 1378 10.1016/j.cell.2015.08.031 26359988 · DOI
  125. [142]Munoz-Canoves P. Scheele C. Pedersen B.K. Serrano A.L. Interleukin-6 myokine signaling in skeletal muscle: A double-edged sword? FEBS J. 2013 280 4131 4148 10.1111/febs.12338 23663276 PMC4163639 · DOI · Paper page
  126. [144]Baltgalvis K.A. Berger F.G. Pena M.M.O. Davis J.M. Muga S.J. Carson J.A. Interleukin-6 and cachexia in ApcMin/+ mice Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008 294 R393 R401 10.1152/ajpregu.00716.2007 18056981 · DOI
  127. [146]Bayliss T.J. Smith J.T. Schuster M. Dragnev K.H. Rigas J.R. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer Expert Opin. Biol. Ther. 2011 11 1663 1668 10.1517/14712598.2011.627850 21995322 · DOI
  128. [149]Aversa Z. Pin F. Lucia S. Penna F. Verzaro R. Fazi M. Colasante G. Tirone A. Rossi Fanelli F. Ramaccini C. Autophagy is induced in the skeletal muscle of cachectic cancer patients Sci. Rep. 2016 6 30340 10.1038/srep30340 27459917 PMC4962093 · DOI
  129. [150]Penna F. Costamagna D. Pin F. Camperi A. Fanzani A. Chiarpotto E.M. Cavallini G. Bonelli G. Baccino F.M. Costelli P. Autophagic degradation contributes to muscle wasting in cancer cachexia Am. J. Pathol. 2013 182 1367 1378 10.1016/j.ajpath.2012.12.023 23395093 · DOI
  130. [151]You L. Wang Z. Li H. Shou J. Jing Z. Xie J. Sui X. Pan H. Han W. The role of STAT3 in autophagy Autophagy 2015 11 729 739 10.1080/15548627.2015.1017192 25951043 PMC4509450 · DOI · Paper page
  131. [152]Pettersen K. Andersen S. Degen S. Tadini V. Grosjean J. Hatakeyama S. Tesfahun A.N. Moestue S. Kim J. Nonstad U. Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling Sci. Rep. 2017 7 2046 10.1038/s41598-017-02088-2 28515477 PMC5435723 · DOI
  132. [153]Kir S. Spiegelman B.M. Cachexia & Brown Fat: A Burning Issue in Cancer Trends Cancer 2016 2 461 463 28459108 PMC5407404
  133. [154]Han J. Meng Q. Shen L. Wu G. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning Lipids Health Dis. 2018 17 14 10.1186/s12944-018-0657-0 29338749 PMC5771021 · DOI
  134. [155]Derecka M. Gornicka A. Koralov S.B. Szczepanek K. Morgan M. Raje V. Sisler J. Zhang Q. Otero D. Cichy J. Tyk2 and Stat3 regulate brown adipose tissue differentiation and obesity Cell Metab. 2012 16 814 824 10.1016/j.cmet.2012.11.005 23217260 PMC3522427 · DOI
  135. [156]Babaei R. Schuster M. Meln I. Lerch S. Ghandour R.A. Pisani D.F. Bayindir-Buchhalter I. Marx J. Wu S. Schoiswohl G. Jak-TGFbeta cross-talk links transient adipose tissue inflammation to beige adipogenesis Sci. Signal. 2018 11 10.1126/scisignal.aai7838 29692363 · DOI · Paper page
  136. [158]Tsoli M. Schweiger M. Vanniasinghe A.S. Painter A. Zechner R. Clarke S. Robertson G. Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation PLoS ONE 2014 9 e92966 10.1371/journal.pone.0092966 24667661 PMC3965507 · DOI
  137. [159]Cernkovich E.R. Deng J. Bond M.C. Combs T.P. Harp J.B. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity Endocrinology 2008 149 1581 1590 10.1210/en.2007-1148 18096662 PMC2276706 · DOI · Paper page
  138. [161]Koltes D.A. Spurlock M.E. Spurlock D.M. Adipose triglyceride lipase protein abundance and translocation to the lipid droplet increase during leptin-induced lipolysis in bovine adipocytes Domest. Anim. Endocrinol. 2017 61 62 76 10.1016/j.domaniend.2017.06.001 28715671 · DOI
  139. [163]Tseng Y.-C. Liva S.G. Dauki A.M. Henderson S.E. Kuo Y.-C. Benedict J.A. Kulp S.K. Bekaii-Saab T. Chen C.-S. Coss C.C. Combined Androgen Administration and HDAC Inhibition in Experimental Cancer Cachexia bioRxiv 2017 214155 10.1101/214155 · DOI
  140. [164]Wynn T.A. Cellular and molecular mechanisms of fibrosis J. Pathol. 2008 214 199 210 10.1002/path.2277 18161745 PMC2693329 · DOI · Paper page
  141. [166]Rosenbloom J. Mendoza F.A. Jimenez S.A. Strategies for anti-fibrotic therapies Biochim. Biophys. Acta 2013 1832 1088 1103 10.1016/j.bbadis.2012.12.007 23266403 · DOI
  142. [168]Hinz B. Phan S.H. Thannickal V.J. Galli A. Bochaton-Piallat M.-L. Gabbiani G. The myofibroblast: One function, multiple origins Am. J. Pathol. 2007 170 1807 1816 10.2353/ajpath.2007.070112 17525249 PMC1899462 · DOI · Paper page
  143. [169]Suwara M.I. Green N.J. Borthwick L.A. Mann J. Mayer-Barber K.D. Barron L. Corris P.A. Farrow S.N. Wynn T.A. Fisher A.J. IL-1alpha released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts Mucosal Immunol. 2014 7 684 693 10.1038/mi.2013.87 24172847 PMC3931585 · DOI
  144. [170]LeBleu V.S. Taduri G. O’Connell J. Teng Y. Cooke V.G. Woda C. Sugimoto H. Kalluri R. Origin and function of myofibroblasts in kidney fibrosis Nat. Med. 2013 19 1047 1053 10.1038/nm.3218 23817022 PMC4067127 · DOI
  145. [171]Piersma B. Bank R.A. Boersema M. Signaling in Fibrosis: TGF-beta, WNT, and YAP/TAZ Converge Front. Med. 2015 2 59 10.3389/fmed.2015.00059 26389119 PMC4558529 · DOI
  146. [172]Meng X.-M. Nikolic-Paterson D.J. Lan H.Y. TGF-beta: The master regulator of fibrosis Nat. Rev. Nephrol. 2016 12 325 338 10.1038/nrneph.2016.48 27108839 · DOI · Paper page
  147. [173]Varga J. Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis Nat. Rev. Rheumatol. 2009 5 200 206 10.1038/nrrheum.2009.26 19337284 PMC3959159 · DOI
  148. [174]Dauer D.J. Ferraro B. Song L. Yu B. Mora L. Buettner R. Enkemann S. Jove R. Haura E.B. Stat3 regulates genes common to both wound healing and cancer Oncogene 2005 24 3397 3408 10.1038/sj.onc.1208469 15735721 · DOI
  149. [175]Sano S. Itami S. Takeda K. Tarutani M. Yamaguchi Y. Miura H. Yoshikawa K. Akira S. Takeda J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis EMBO J. 1999 18 4657 4668 10.1093/emboj/18.17.4657 10469645 PMC1171539 · DOI · Paper page
  150. [176]Ogata H. Chinen T. Yoshida T. Kinjyo I. Takaesu G. Shiraishi H. Iida M. Kobayashi T. Yoshimura A. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production Oncogene 2006 25 2520 2530 10.1038/sj.onc.1209281 16474852 · DOI · Paper page
  151. [178]Li C. Iness A. Yoon J. Grider J.R. Murthy K.S. Kellum J.M. Kuemmerle J.F. Noncanonical STAT3 activation regulates excess TGF-beta1 and collagen I expression in muscle of stricturing Crohn’s disease J. Immunol. 2015 194 3422 3431 10.4049/jimmunol.1401779 25740948 PMC4369432 · DOI
  152. [179]Seo H.-Y. Jeon J.-H. Jung Y.-A. Jung G.-S. Lee E.J. Choi Y.-K. Park K.-G. Choe M.S. Jang B.K. Kim M.-K. Fyn deficiency attenuates renal fibrosis by inhibition of phospho-STAT3 Kidney Int. 2016 90 1285 1297 10.1016/j.kint.2016.06.038 27616741 · DOI
  153. [180]Giannandrea M. Parks W.C. Diverse functions of matrix metalloproteinases during fibrosis Dis. Models Mech. 2014 7 193 203 10.1242/dmm.012062 24713275 PMC3917240 · DOI
  154. [181]Wang X. Zhou Y. Tan R. Xiong M. He W. Fang L. Wen P. Jiang L. Yang J. Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy Am. J. Physiol. Renal Physiol. 2010 299 F973 F982 10.1152/ajprenal.00216.2010 20844022 · DOI
  155. [182]Matsui F. Babitz S.A. Rhee A. Hile K.L. Zhang H. Meldrum K.K. Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production Am. J. Physiol. Renal Physiol. 2017 312 F25 F32 10.1152/ajprenal.00311.2016 27760767 PMC5283885 · DOI
  156. [183]Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells J. Signal Transduct. 2010 2010 985132 10.1155/2010/985132 21152266 PMC2997758 · DOI
  157. [184]Wang H. Lafdil F. Wang L. Yin S. Feng D. Gao B. Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: Involvement of hepatocyte STAT3 in TIMP-1 production Cell Biosci. 2011 1 14 10.1186/2045-3701-1-14 21711826 PMC3125204 · DOI
  158. [185]Hirano T. Ishihara K. Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors Oncogene 2000 19 2548 2556 10.1038/sj.onc.1203551 10851053 · DOI
  159. [186]Moodley Y.P. Misso N.L.A. Scaffidi A.K. Fogel-Petrovic M. McAnulty R.J. Laurent G.J. Thompson P.J. Knight D.A. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs Am. J. Respir. Cell Mol. Biol. 2003 29 490 498 10.1165/rcmb.2002-0262OC 12714376 · DOI
  160. [187]Habiel D.M. Hogaboam C. Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis Front. Pharmacol. 2014 5 2 10.3389/fphar.2014.00002 24478703 PMC3899580 · DOI
  161. [188]Xu M.-Y. Hu J.-J. Shen J. Wang M.-L. Zhang Q.-Q. Qu Y. Lu L.-G. Stat3 signaling activation crosslinking of TGF-beta1 in hepatic stellate cell exacerbates liver injury and fibrosis Biochim. Biophys. Acta 2014 1842 2237 2245 10.1016/j.bbadis.2014.07.025 25092172 · DOI
  162. [189]Gujral T.S. Chan M. Peshkin L. Sorger P.K. Kirschner M.W. MacBeath G. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis Cell 2014 159 844 856 10.1016/j.cell.2014.10.032 25417160 PMC4243058 · DOI
  163. [190]Guo L. Chen C. Shi M. Wang F. Chen X. Diao D. Hu M. Yu M. Qian L. Guo N. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition Oncogene 2013 32 5272 5282 10.1038/onc.2012.573 23318420 · DOI
  164. [191]Balanis N. Wendt M.K. Schiemann B.J. Wang Z. Schiemann W.P. Carlin C.R. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway J. Biol. Chem. 2013 288 17954 17967 10.1074/jbc.M113.475277 23653350 PMC3689941 · DOI
  165. [192]Saitoh M. Endo K. Furuya S. Minami M. Fukasawa A. Imamura T. Miyazawa K. STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression Oncogene 2016 35 1049 1057 10.1038/onc.2015.161 25961936 · DOI
  166. [193]Liu J. Zhong Y. Liu G. Zhang X. Xiao B. Huang S. Liu H. He L. Role of Stat3 Signaling in Control of EMT of Tubular Epithelial Cells During Renal Fibrosis Cell. Physiol. Biochem. 2017 42 2552 2558 10.1159/000480216 28848189 · DOI
  167. [194]Lamouille S. Xu J. Derynck R. Molecular mechanisms of epithelial-mesenchymal transition Nat. Rev. Mol. Cell Biol. 2014 15 178 196 10.1038/nrm3758 24556840 PMC4240281 · DOI · Paper page
  168. [196]O’Reilly S. Ciechomska M. Cant R. van Laar J.M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein J. Biol. Chem. 2014 289 9952 9960 10.1074/jbc.M113.545822 24550394 PMC3975039 · DOI
  169. [197]Wang G. Yu Y. Sun C. Liu T. Liang T. Zhan L. Lin X. Feng X.-H. STAT3 selectively interacts with Smad3 to antagonize TGF-beta Oncogene 2016 35 4388 4398 10.1038/onc.2015.446 26616859 PMC4885808 · DOI
  170. [198]Khanna D. Denton C.P. Jahreis A. van Laar J.M. Frech T.M. Anderson M.E. Baron M. Chung L. Fierlbeck G. Lakshminarayanan S. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial Lancet 2016 387 2630 2640 10.1016/S0140-6736(16)00232-4 27156934 · DOI · Paper page
  171. [199]Wang L.H. Yang X.Y. Zhang X. Huang J. Hou J. Li J. Xiong H. Mihalic K. Zhu H. Xiao W. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells Immunity 2004 20 205 218 10.1016/S1074-7613(04)00030-5 14975242 · DOI
  172. [200]Calvier L. Chouvarine P. Legchenko E. Hoffmann N. Geldner J. Borchert P. Jonigk D. Mozes M.M. Hansmann G. PPARgamma Links BMP2 and TGFbeta1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism Cell Metab. 2017 25 1118 1134.e7 10.1016/j.cmet.2017.03.011 28467929 · DOI
  173. [201]Agha El E. Moiseenko A. Kheirollahi V. De Langhe S. Crnkovic S. Kwapiszewska G. Szibor M. Kosanovic D. Schwind F. Schermuly R.T. Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis Cell Stem Cell 2017 20 261 273 10.1016/j.stem.2016.10.004 27867035 PMC5291816 · DOI · Paper page
  174. [202]Nunez Lopez O. Bohanon F.J. Wang X. Ye N. Corsello T. Rojas-Khalil Y. Chen H. Chen H. Zhou J. Radhakrishnan R.S. STAT3 Inhibition Suppresses Hepatic Stellate Cell Fibrogenesis: HJC0123, a Potential Therapeutic Agent for Liver Fibrosis RSC Adv. 2016 6 100652 100663 10.1039/C6RA17459K 28546859 PMC5440088 · DOI
  175. [203]Waitkus M.S. Chandrasekharan U.M. Willard B. Tee T.L. Hsieh J.K. Przybycin C.G. Rini B.I. Dicorleto P.E. Signal integration and gene induction by a functionally distinct STAT3 phosphoform Mol. Cell. Biol. 2014 34 1800 1811 10.1128/MCB.00034-14 24615012 PMC4019034 · DOI · Paper page
  176. [204]Waitkus M.S. Chandrasekharan U.M. Willard B. Haque S.J. Dicorleto P.E. STAT3-mediated coincidence detection regulates noncanonical immediate early gene induction J. Biol. Chem. 2013 288 11988 12003 10.1074/jbc.M112.428516 23504318 PMC3636885 · DOI
  177. [205]Leung J.Y. Wilson H.L. Voltzke K.J. Williams L.A. Lee H.J. Wobker S.E. Kim W.Y. Sav1 Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis Mol. Cell. Biol. 2017 37 e00565-16 10.1128/MCB.00565-16 28320873 PMC5452723 · DOI
  178. [206]Ma J.F. Sanchez B.J. Hall D.T. Tremblay A.-M.K. Di Marco S. Gallouzi I.-E. STAT3 promotes IFNgamma/TNFalpha-induced muscle wasting in an NF-kappaB-dependent and IL-6-independent manner EMBO Mol. Med. 2017 9 622 637 10.15252/emmm.201607052 28264935 PMC5412921 · DOI

Cited by

Sorted by citations

Authors
Kasembeli, M. M., Bharadwaj, U., Robinson, P., & Tweardy, D. J.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Tweardy, David J.
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2018-08-05
Volume
19
Issue
8
Pages
2299
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms19082299
PMC
PMC6121470
OpenAlex
W2885074747
Cited by
199
References
24
Citations by year
2026: 21 · 2025: 29 · 2024: 28 · 2023: 32 · 2022: 27 · 2021: 35 · 2020: 16 · 2019: 9 · 2018: 2
FWCI
1.62
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University of Texas MD Anderson Cancer Center
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords
STAT3, chronic inflammation, fibrosis, IL-6 family cytokines, cytokine signaling, host response to injury
MeSH terms
Animals, Asthma, Cachexia, Colitis, Ulcerative, Crohn Disease, Fibrosis, Humans, STAT3 Transcription Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review